Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit. METHODS: Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression. Predictive effects of high vs low EREG on OS and progression-free survival (PFS) were examined for treatment-biomarker interaction. RESULTS: Both EREG and K-ras status were ascertained in 385 (193 cetuximab, 192 BSC) tumour samples. Within the high EREG and K-ras wild-type status ('co-biomarker')-positive group (n=139, 36%), median PFS was 5.4 vs 1.9 months (hazard ratio (HR) 0.31; P<0.0001), and median OS was 9.8 vs 5.1 months (HR 0.43; P<0.001) for cetuximab vs BSC, respectively. In the rest (n=246, 64%), PFS (HR 0.82; P=0.12) and OS (HR 0.90; P=0.45) were not significantly different. Test for treatment interaction showed a larger cetuximab effect on OS (HR 0.52; P=0.007) and PFS (HR 0.49; P=0.001) in the co-biomarker-positive group. CONCLUSION: In pre-treated K-ras wild-type status colorectal cancer, patients with high EREG gene expression appear to benefit more from cetuximab therapy compared with low expression. Epiregulin as a selective biomarker requires further evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 2×
“…Gastro-Intestinal Trials Group (AGITG), cetuximabþ best supportive care (BSC) improves overall survival (OS) and progression-free survival (PFS), and better preserves quality of life for advanced chemotherapy–refractory colorectal cancer compared with BSC alone (Au et al, 2009; Jonker et al, 2007).”
BackgroundSelf-citationJacobs, B., De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., Vandesompele, J., Peeters, M., Van Laethem, J.-L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3744 · Cited by 368 · cited 1×
“Subsequently, tumour EREG and AREG mRNA expression were evaluated in 220 patients with chemotherapy–refractory colorectal cancer treated with cetuximab plus irinotecan (Jacobs et al, 2009).”
BackgroundPentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-49 · Cited by 111
Cited by
Sorich, M. J., Wiese, M. D., Rowland, A., Kichenadasse, G., McKinnon, R. A., & Karapetis, C. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu378 · Cited by 540
Self-citationSchütte, M., Risch, T., Abdavi-Azar, N., Boehnke, K., Schumacher, D., Keil, M., Yildiriman, R., Jandrasits, C., Borodina, T., Amstislavskiy, V., et al. (2017) · Nature Communications · doi:10.1038/ncomms14262 · Cited by 339
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30798-3 · Cited by 255
Seligmann, J. F., Elliott, F., Richman, S. D., Jacobs, B., Hemmings, G., Brown, S., Barrett, J. H., Tejpar, S., Quirke, P., & Seymour, M. T. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.6065 · Cited by 113
Beyond KRAS Status and Response to Anti-EGFR Therapy in Metastatic Colorectal Cancer
Perkins, G., Pilati, C., Blons, H., & Laurent-Puig, P. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.66 · Cited by 22
Metadata
- Authors
- Jonker, D. J., Karapetis, C. S., Harbison, C., O'Callaghan, C. J., Tu, D., Simes, R. J., Malone, D. P., Langer, C., Tebbutt, N., Price, T. J., Shapiro, J., Siu, L. L., Wong, R. P. W., Bjarnason, G., Moore, M. J., Zalcberg, J. R., & Khambata-Ford, S.
- Venue
- British Journal of Cancer
- Published
- 2013-12-12
- Volume
- 110
- Issue
- 3
- Pages
- 648-655
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2055443426
- Cited by
- 88
- References
- 4
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. https://app.cochat.ai/papers/10.1038/bjc.2013.753
- The paper
- Jonker, D. J., Karapetis, C. S., Harbison, C., O'Callaghan, C. J., Tu, D., Simes, R. J., Malone, D. P., Langer, C., Tebbutt, N., Price, T. J., Shapiro, J., Siu, L. L., Wong, R. P. W., Bjarnason, G., Moore, M. J., Zalcberg, J. R., & Khambata-Ford, S. (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.2013.753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.